SOURCE-LINKED STUDY SUMMARY
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?
Abstract summarizedQuality not appraised
- What was studied
- Researchers examined whether reports linking semaglutide to a type of optic-nerve injury reflected reporting patterns or drug effects.
- Who / model studied
- They analysed US adverse-event reports from 2018 through the second quarter of 2026 and genetic proxies for GLP-1 receptor activity. Report and genetic sample sizes are not stated.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Reporting increased after a July 2024 publication, while comparator reporting stayed stable. The genetic-proxy analysis found no statistically clear effect on the examined eye measures. The authors interpreted these patterns as reporting bias; adverse-report frequency is not a measured incidence rate among treated patients.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.64898/2026.09.06.26362369